Provided by Tiger Fintech (Singapore) Pte. Ltd.

Omeros

3.00
-0.2000-6.25%
Post-market: 3.150.1500+5.00%16:52 EDT
Volume:1.24M
Turnover:3.80M
Market Cap:175.78M
PE:-1.14
High:3.20
Open:3.20
Low:2.98
Close:3.20
Loading ...

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Business Wire
·
01 Apr

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
31 Mar

OMER S.p.a. Receives Buy Rating from Gianluca Bertuzzo FCA Due to Strong Performance and Promising Future Prospects

TIPRANKS
·
31 Mar

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Benzinga
·
28 Mar

Omeros Corp expected to post a loss of 78 cents a share - Earnings Preview

Reuters
·
28 Mar

Strong Buy Rating for Omeros Corporation Driven by Promising Narsoplimab Prospects and Strategic Advancements

TIPRANKS
·
27 Mar

Press Release: Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Dow Jones
·
26 Mar

Omeros Is Maintained at Buy by D. Boral Capital

Dow Jones
·
22 Mar

Omeros Says Trial Site Activation Underway for Phase 3 Study of Zaltenibart

MT Newswires Live
·
22 Mar

Omeros Corp - Phase 3 Data Needed for Bla Submission Expected in Q4 2026

THOMSON REUTERS
·
21 Mar

Omeros Corp - No Safety Signal of Concern Has Been Observed With Zaltenibart

THOMSON REUTERS
·
21 Mar

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 Pnh Clinical Trial Program

THOMSON REUTERS
·
21 Mar

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Business Wire
·
21 Mar

BRIEF-Omeros Corporation Receives Commitment Of Over $4 Million From Nida For Further Development Of The Company’S Oms527 Program To Treat Cocaine Use Disorder

Reuters
·
13 Mar

Omeros Corporation Receives Commitment of Over $4 Million From Nida for Further Development of the Company’s Oms527 Program to Treat Cocaine Use Disorder

THOMSON REUTERS
·
13 Mar

Top Premarket Decliners

MT Newswires Live
·
07 Mar

Investors Look for Signs of Tariff Easing as US Futures Rise Modestly Pre-Bell

MT Newswires Live
·
05 Mar

Omeros announces results for narsoplimab expanded access program

TipRanks
·
21 Feb

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Business Wire
·
14 Feb

OMER S.p.a. Receives ‘Buy’ Rating Following Strategic Luxury Train Project and Anticipated Revenue Growth

TIPRANKS
·
13 Feb